These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9644287)

  • 21. Polar-phase indices of perioral muscle reciprocity during syllable production in Parkinson's disease.
    Chu SY; Barlow SM; Lee J; Wang J
    Int J Speech Lang Pathol; 2017 Dec; 19(6):616-627. PubMed ID: 28425760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
    Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
    Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of levodopa on vocal function in Parkinson's disease.
    Sanabria J; Ruiz PG; Gutierrez R; Marquez F; Escobar P; Gentil M; Cenjor C
    Clin Neuropharmacol; 2001; 24(2):99-102. PubMed ID: 11307045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa and executive performance in Parkinson's disease: a randomized study.
    Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
    J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Swallowing improvement after levodopa treatment in idiopathic Parkinson's disease: lack of evidence.
    Melo A; Monteiro L
    Parkinsonism Relat Disord; 2013 Mar; 19(3):279-81. PubMed ID: 23231973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
    Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
    J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.
    Esposito F; Tessitore A; Giordano A; De Micco R; Paccone A; Conforti R; Pignataro G; Annunziato L; Tedeschi G
    Brain; 2013 Mar; 136(Pt 3):710-25. PubMed ID: 23423673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.
    Kianirad Y; Simuni T
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):34. PubMed ID: 26898686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Speech and voice disorders in Parkinson's disease].
    Martnez-Sánchez F
    Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring the Effect of Levodopa Using Sustained Phonemes in Parkinson's Disease Patients.
    Motin MA; Pah ND; Kumar DK
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38083746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of utterance rate and length on the spatiotemporal index in Parkinson's disease.
    Chu SY; Barlow SM; Lee J; Wang J
    Int J Speech Lang Pathol; 2020 Apr; 22(2):141-151. PubMed ID: 31213093
    [No Abstract]   [Full Text] [Related]  

  • 34. [Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
    Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Domokos LC; Vajda T; Orbán-Kis K
    Orv Hetil; 2019 Apr; 160(17):662-669. PubMed ID: 31010306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.
    Prakash KM; Kek PC
    Parkinsonism Relat Disord; 2010 Dec; 16(10):691-2. PubMed ID: 20729126
    [No Abstract]   [Full Text] [Related]  

  • 37. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The variability of levodopa response in Parkinson's disease: is sensitization reversible?
    Jabre MG; Bejjani BP
    Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452
    [No Abstract]   [Full Text] [Related]  

  • 40. Resolution of inverse psoriasis after treatment with levodopa for Parkinson's disease.
    Rojo Suárez N; Jiménez Gallo D; Arjona Aguilera C; Espinosa Rosso R; Linares Barrios M
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27550839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.